Nevertheless, we strongly believe that all these results make DCN an interesting candidate for future treatments of glaucoma due to its ability to reduce expression and synthesis as well as activity of TGF-β and CTGF/CCN2 in human and murine astrocytes of the ON and ONH. The gene discussed is TGFB1; the disease is glaucoma.